Fraidenburg, Dustin, Jason Yuan. Current and future targets for pulmonary arterial hypertension. High Alt Med Biol 14:134–143, 2013.—Pulmonary arterial hypertension (PAH) remains a poorly understood disorder with dire consequences. Progression of disease often leads to right heart failure and death without lung transplantation. Limited therapeutic strategies exist for the treatment of PAH and current medical treatment consists of two major categories, supportive care therapeutics and pulmonary vasculature targeted therapy. Supportive care includes anticoagulants and inotropic agents, while pulmonary vasculature targets currently available include endothelin antagonists, phosphodiesterase inhibitors and prostacyclin analogs. While these therapies have shown efficacy in hemodynamic and functional outcomes; halting the progression of disease, reversal, and clinical cure has been elusive. Combination therapy and newer agents may provide innovative insight into the disease process and ultimately change the prognosis of this fatal disease. By utilizing specific targets on the cell membrane, second messengers systems or signaling peptides, novel therapeutic strategies will hopefully emerge. In this review we discuss the currently available therapeutic options and their pulmonary vasculature targets as well as some future therapeutic targets that have promising results in human trials.
Get full access to this article
View all access options for this article.
References
1.
AcostaF, SansanoT, PalencianoCGet al.2005. Effects of dobutamine on right ventricular function and pulmonary circulation in pulmonary hypertension during liver transplantation. Transplant Proc, 37:3869–3870.
2.
AldashevAA, KojonazarovBK, AmatovTAet al.2005. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax, 60:683–687.
3.
BarretoAC, MaedaNY, SoaresRP, CiceroC, LopesAA. 2008. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: A placebo-controlled study. Braz J Med Biol Res, 41:657–663.
4.
BarstRJ, McGoonM, McLaughlinVet al.2003. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 41:2119–2125.
5.
BarstRJ, OudizRJ, BeardsworthAet al.2011. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant, 30:632–643.
6.
BarstRJ, RubinLJ, LongWAet al.1996. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med, 334:296–301.
7.
BatesMG, ThompsonAA, BaillieJKet al.2011. Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: Double blind, randomized, placebo-controlled trial. High Alt Med Biol, 12:207–214.
8.
BenzaRL, MillerDP, BarstRJ, BadeschDB, FrostAE, McGoonMD. 2012. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest, 142:448–456.
9.
ChristmanBW, McPhersonCD, NewmanJHet al.1992. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med, 327:70–75.
10.
DempsieY, MacLeanMR. 2008. Pulmonary hypertension: Therapeutic targets within the serotonin system. Br J Pharmacol, 155:455–462.
11.
DesaiAA, MachadoRF. 2011. Diagnostic and therapeutic algorithm for pulmonary arterial hypertension. Pulm Circ, 1:122–124.
12.
DupuisJ, GoreskyCA, FournierA. 1996. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors. J Appl Physiol, 81:1510–1515.
13.
FadelE, MercierO, MussotSet al.2010. Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: A comparative retrospective study of 219 patients. Eur J Cardiothorac Surg, 38:277–284.
14.
FrankH, MlczochJ, HuberK, SchusterE, GurtnerHP, KneusslM. 1997. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest, 112:714–721.
15.
FujitaH, FukumotoY, SajiKet al.2010. Acute vasodilator effects of inhaled fasudil, a specific rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels, 25:144–149.
16.
FukumotoY, TawaraS, ShimokawaH. 2007. Recent progress in the treatment of pulmonary arterial hypertension: Expectation for rho-kinase inhibitors. Tohoku J Exp Med, 211:309–320.
17.
FusterV, SteelePM, EdwardsWD, GershBJ, McGoonMD, FryeRL. 1984. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation, 70:580–587.
GalieN, GhofraniHA, TorbickiAet al.2005. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 353:2148–2157.
20.
GalieN, HoeperMM, GibbsJS, SimonneauG. 2011. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J, 37:475–476.
21.
GalieN, OlschewskiH, OudizRJet al.2008. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation, 117:3010–3019.
22.
GalieN, PalazziniM, ManesA. 2012. Vasoactive intestinal peptide in pulmonary arterial hypertension. Am J Respir Crit Care Med, 185:7.
23.
GalieN, RubinL, HoeperMet al.2008. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet, 371:2093–2100.
24.
GesslerT, SchmehlT, HoeperMMet al.2001. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J, 17:14–19.
25.
GhofraniHA, MorrellNW, HoeperMMet al.2012. Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: Results of a double blind, randomised, prospective phase IIa study. Am J Respir Crit Care Med
26.
GhofraniHA, WiedemannR, RoseFet al.2002. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med, 136:515–522.
27.
GhofraniHA, HoeperMM, HalankMet al.2010. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J, 36:792–799.
28.
GhofraniHAet al.2012. Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: A randomized, double-blind, placebo-controlled study (CHEST-1)ACCP Atlanta: USAOral abstract 1462924.
29.
GhofraniHAet al.2012. Riociguat for the treatment of pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled study (PATENT-1)CHEST 2012: Atlanta, USAAbstract 1462799.
30.
GiaidA, YanagisawaM, LanglebenDet al.1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 328:1732–1739.
31.
GrimmingerF, WeimannG, FreyRet al.2009. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J, 33:785–792.
32.
HeathD. 1989. Missing link from Tibet. Thorax, 44:981–983.
33.
HeathD, WilliamsD, Rios-DalenzJ, CalderonM, GosneyJ. 1990. Small pulmonary arterial vessels of Aymara Indians from the Bolivian andes. Histopathology, 16:565–571.
34.
HirataY, EmoriT, EguchiSet al.1993. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest, 91:1367–1373.
35.
HiremathJ, ThanikachalamS, ParikhKet al.2010. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial. J Heart Lung Transplant, 29:137–149.
36.
HoeperMet al.Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES)Data presented at the European Respiratory Society (ERS) Annual Congress. Abstract No. 413PresentedSeptember 25, 2011,
37.
HoeperMM, SchwarzeM, EhlerdingSet al.2000. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med, 342:1866–1870.
38.
HuangS, DeSantisER. 2007. Treatment of pulmonary arterial hypertension in pregnancy. Am J Health Syst Pharm, 64:1922–1926.
39.
HumbertM, BarstRJ, RobbinsIMet al.2004. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J, 24:353–359.
40.
HumbertM, MontiG, FartoukhMet al.1998. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients. Eur Respir J, 11:554–559.
41.
JingZC, YuZX, ShenJYet al.2011. Vardenafil in pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med, 183:1723–1729.
42.
KaoPN. 2005. Simvastatin treatment of pulmonary hypertension: An observational case series. Chest, 127:1446–1452.
43.
KawutSM, BagiellaE, LedererDJet al.2011. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation, 123:2985–2993.
44.
KeoghAM, MayerE, BenzaRLet al.2009. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol, 54,1 Suppl:S67–77.
45.
KojonazarovB, IsakovaJ, ImanovBet al.2012. Bosentan reduces pulmonary artery pressure in high altitude residents. High Alt Med Biol, 13:217–223.
46.
KojonazarovB, MyrzaakhmatovaA, SooronbaevT, IshizakiT, AldashevA. 2012. Effects of fasudil in patients with high-altitude pulmonary hypertension. Eur Respir J, 39:496–498.
47.
LavelleA, SugrueR, LawlerGet al.2009. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J, 34:770–771.
48.
LawMA, GrifkaRG, MullinsCE, NihillMR. 2007. Atrial septostomy improves survival in select patients with pulmonary hypertension. Am Heart J, 153:779–784.
49.
LeuchteHH, BaeznerC, BaumgartnerRAet al.2008. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J, 32:1289–1294.
50.
LevinER. 1995. Endothelins. N Engl J Med, 333:356–363.
51.
MacleanMR, DempsieY. 2010. The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol, 661:309–322.
52.
MarcosE, FadelE, SanchezOet al.2004. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res, 94:1263–1270.
53.
MathaiSC, GirgisRE, FisherMRet al.2007. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J, 29:469–475.
54.
McLaughlinVV, ArcherSL, BadeschDBet al.2009. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. A report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol, 53:1573–1619.
55.
McLaughlinVV, BenzaRL, RubinLJet al.2010. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol, 55:1915–1922.
56.
McLaughlinVV, GaineSP, BarstRJet al.2003. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol, 41:293–299.
57.
McLaughlinVV, OudizRJ, FrostAet al.2006. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med, 174:1257–1263.
58.
MorrisonK, ErnstR, HessP, StuderR, ClozelM. 2010. Selexipag: A selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther, 335:249–255.
59.
MuraliS, UretskyBF, ReddyPS, TokarczykTR, BetschartAR. 1991. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: Comparative effects of various pharmacologic agents. Am Heart J, 122:1375–1381.
60.
NagayaN, KyotaniS, UematsuMet al.2004. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation, 109:351–356.
61.
NagayaN, NishikimiT, UematsuMet al.2000. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart, 84:653–658.
62.
NakamuraM, YoshidaH, MakitaS, ArakawaN, NiinumaH, HiramoriK. 1997. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation, 95:1214–1221.
63.
OlschewskiH, RoseF, SchermulyRet al.2004. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther, 102:139–153.
64.
OlschewskiH, SimonneauG, GalieNet al.2002. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med, 347:322–329.
65.
OlschewskiH, WalmrathD, SchermulyR, GhofraniA, GrimmingerF, SeegerW. 1996. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med, 124:820–824.
66.
PagnamentaA, FeslerP, VandinivitA, BrimioulleS, NaeijeR. 2003. Pulmonary vascular effects of dobutamine in experimental pulmonary hypertension. Crit Care Med, 31:1140–1146.
67.
PietraGG, EdwardsWD, KayJMet al.1989. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, primary pulmonary hypertension registry. Circulation, 80:1198–1206.
68.
RichS, KaufmannE, LevyPS. 1992. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med, 327:76–81.
69.
RichS, SeidlitzM, DodinEet al.1998. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest, 114:787–792.
70.
RichaletJP, GratadourP, RobachPet al.2005. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med, 171:275–281.
71.
RobbinsIM, KawutSM, YungDet al.2006. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J, 27:578–584.
72.
RosenRC, KostisJB. 2003. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol, 92:9M–18M.
73.
RubinLJ, BadeschDB, BarstRJet al.2002. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 346:896–903.
SeoB, OemarBS, SiebenmannR, von SegesserL, LuscherTF. 1994. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation, 89:1203–1208.
77.
SidhartaPN, van GiersbergenPL, HalabiA, DingemanseJ. 2011. Macitentan: Entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol, 67:977–984.
78.
SimonneauG, RobbinsIM, BeghettiMet al.2009. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 54:S43–54.
79.
SimonneauG, RubinLJ, GalieNet al.2008. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med, 149:521–530.
80.
SimonneauG, TorbickiA, HoeperMMet al.2012. Selexipag: An oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J, 40:874–880.
81.
SitbonO, HumbertM, JagotJLet al.1998. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J, 12:265–270.
82.
SitbonO, HumbertM, JaisXet al.2005. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation, 111:3105–3111.
83.
SitbonO, JaisX, SavaleLet al.2011. Upfront triple combination therapy of i.v. epoprostenol with oral bosentan and sildenafil in idiopathic and heritable pulmonary arterial hypertension. Am J Respir Crit Care Med, 183:A5910.
84.
SmithJS, MuellerJ, DanielsCJ. 2012. Pulmonary arterial hypertension in the setting of pregnancy: A case series and standard treatment approach. Lung, 190:155–160.
85.
SztrymfB, SouzaR, BertolettiLet al.2010. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J, 35:1286–1293.
86.
TapsonVF, TorresF, KermeenFet al.2012. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial. Chest, 142:1383–1390.
VoswinckelR, ReichenbergerF, GallHet al.2009. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther, 22:50–56.
89.
WilkinsMR, AliO, BradlowWet al.2010. Simvastatin as a treatment for pulmonary hypertension trial (SiPHT)Am J Respir Crit Care Med, 181:1106–1113.
90.
YanagisawaM, KuriharaH, KimuraSet al.1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 332:411–415.
